Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating

NodeGuardian · 2026-03-13T20:09:04+00:00

Evercore ISI increased its price target for AbbVie shares to $233, up from $228, while keeping an Outperform rating, reflecting optimism about the company's prospects and recent drug trial updates.

NodeGuardian

2026-03-13 20:09:04

Geração de resumo em curso

Evercore ISI has raised its price target for AbbVie (ABBV) shares to $233 from $228, while maintaining an Outperform rating on the pharmaceutical company. This adjustment reflects Evercore ISI’s continued positive outlook on AbbVie’s performance. The article also provides recent news about AbbVie, including developments in its drug trials and financial activities.

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.